Reference : Phase I/II studies to evaluate safety and immunogenicity of a recombinant gp350 Epste...
Scientific journals : Article
Life sciences : Veterinary medicine & animal health
Human health sciences : Laboratory medicine & medical technology
Human health sciences : Immunology & infectious disease
Phase I/II studies to evaluate safety and immunogenicity of a recombinant gp350 Epstein-Barr virus vaccine in healthy adults
Moutschen, Michel mailto [Université de Liège - ULiège > Département des sciences cliniques > Immunopathologie - Transplantation]
Leonard, Philippe mailto [Centre Hospitalier Universitaire de Liège - CHU > > Maladies infectieuses et médecine interne générale >]
Sokal, E. M. [> > > >]
Smets, F. [> > > >]
Haumont, M. [> > > >]
Mazzu, P. [> > > >]
Bollen, A. [> > > >]
Denamur, F. [> > > >]
Peeters, P. [> > > >]
Dubin, G. [> > > >]
Denis, M. [> > > >]
Elsevier Sci Ltd
Yes (verified by ORBi)
[en] Epstein-Barr virus (EBV) ; vaccine ; gp350
[en] Two double-blind randomised controlled studies (phase I and I/II) were performed to assess for the first time the safety and immunogenicity of a recombinant subunit gp350 Epstein-Barr virus (EBV) vaccine in 148 healthy adult volunteers. All candidate vaccine formulations had a good safety profile and were well tolerated, with the incidence of solicited and unsolicited symptoms within a clinically acceptable range. One serious adverse event was reported in the phase I trial which was considered to be of suspected relationship to vaccination. The gp350 vaccine formulations were immunogenic and induced gp350-specific antibody responses (including neutralising antibodies). (c) 2007 Elsevier Ltd. All rights reserved.

File(s) associated to this reference

Fulltext file(s):

Restricted access
Recombinant gp350 vaccine for infectious mononucleosis - 2007.pdfAuthor postprint110.25 kBRequest copy

Bookmark and Share SFX Query

All documents in ORBi are protected by a user license.